Evidence map›Paper›PMID 32348165›Full record

ReviewHealth security

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

John Billington, Isabelle Deschamps, Stanley C Erck, Julie L Gerberding, Emmanuel Hanon, Sabrina Ivol, John W Shiver, Julia A Spencer, Johan Van Hoof

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Health security. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Development of vaccine formulations: past, present, and future.Drug delivery and translational research · 2021
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Reflections on the COVID-19 pandemic in the USA: Will we be better prepared next time?International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John BillingtonJohn Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.
Isabelle DeschampsIsabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.
Stanley C ErckStanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD.
Julie L GerberdingJulie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.
Emmanuel HanonJohn Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.
Sabrina IvolSabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.
John W ShiverIsabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.
Julia A SpencerJulie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.
Johan Van HoofSabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.

Indexed as

Global HealthCommunicable Disease ControlCommunicable Diseases, EmergingCoronavirus InfectionsCOVID-19Drug ApprovalDrug DevelopmentDrug IndustryFemaleHumansInfluenza VaccinesMaleNeeds AssessmentPandemicsPneumonia, ViralPublic HealthInfluenza VaccinesCOVID-19Epidemic management/responseInfectious diseasesSARS-CoV-2Vaccine development

Identifiers

PMID32348165
PMCPMC7310201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.